F10 and atrial fibrillation: In recent years, non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) including the direct thrombin inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban, have greatly improved anticoagulation therapy for the prevention of stroke and systemic embolism in patients with AF.